Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors

Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?

(2021) Andrew B Lassman et al.   NEURO-ONCOLOGY

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

(2021) Martin J van den Bent et al.   LANCET ONCOLOGY

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

(2021) David N Louis et al.   NEURO-ONCOLOGY

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

(2020) Erica H. Bell et al.   JOURNAL OF CLINICAL ONCOLOGY

CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.

(2020) Kurt A Jaeckle et al.   NEURO-ONCOLOGY

Biomarkers in NOA-04: another piece to the puzzle

(2016) Andrew B. Lassman et al.   NEURO-ONCOLOGY

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

(2016) Jan C. Buckner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial

(2015) Hendrikus J. Dubbink et al.   NEURO-ONCOLOGY

Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH

(2014) J. Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics

(2014) Walter Taal et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

(2013) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors

(2013) Esther J. J. Habets et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial treatment patterns over time for anaplastic oligodendroglial tumors

(2012) K. S. Panageas et al.   NEURO-ONCOLOGY

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

(2011) A. B. Lassman et al.   NEURO-ONCOLOGY

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE